Business Context and Reporting Period
This Form 8-K was filed by Aileron Therapeutics, Inc. (trading symbol: ALRN) on September 28, 2019. The filing reports on interim results from an ongoing Phase 2a clinical trial presented at the 2019 Congress of the European Society for Medical Oncology (ESMO). The trial evaluates the combination of ALRN-6924 and Pfizer's IBRANCE (palbociclib) for treating patients with tumors harboring wild-type p53 and MDM2 amplification or MDM2/CDK4 co-amplification.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. As a clinical-stage biotechnology company reporting on a specific clinical event, this 8-K does not contain financial statements or operational financial metrics.
Material Changes and Clinical Results
The primary material event is the announcement of interim clinical data as of the September 2, 2019 cutoff date:
- Enrollment: 26 patients enrolled in the trial.
- Safety Profile: The combination was well-tolerated. Common non-hematological adverse events (Grade 2+) included nausea (46%) and fatigue (23%). Neutropenia was the only Grade 3+ hematological adverse event occurring in >5% of patients (27%). Grade 3+ thrombocytopenia and leukopenia were observed in only one patient each (3.8%).
- Efficacy in Liposarcoma: In 17 evaluable patients with liposarcoma, the disease control rate was 88%, and median progression-free survival was 4.4 months (with 53% censoring). No partial or complete responses were observed.
Guidance, Outlook, and Risks
Outlook and Plans:
- The Company expects the first indication for the combination may be MDM2-amplified sarcoma, targeting an estimated 15,000 patients diagnosed annually worldwide.
- Enrollment will be expanded to a total of 35 patients to evaluate the combination in other MDM2-amplified cancers.
- A final data readout is expected in the second quarter of 2020.
- Forward-looking statements are subject to risks including insufficient cash resources to fund operations, clinical trial results not being indicative of future results, and regulatory approval uncertainties.
- The Company disclaims any obligation to update forward-looking statements.
Investor Verification Checklist
- Verify the Company's current cash runway and ability to fund the expanded enrollment to 35 patients and operations through the expected Q2 2020 data readout.
- Confirm the definition of "evaluable patients" and the specific criteria for the 88% disease control rate in the liposarcoma cohort.
- Monitor upcoming filings for the final data readout scheduled for Q2 2020 to assess if interim results hold.
- Review the "Risk Factors" section of the Form 10-Q filed on August 6, 2019, for detailed operational and regulatory risks.